Search

Your search keyword '"Iacobelli, Simona"' showing total 7 results
Start Over Author "Iacobelli, Simona" Publication Year Range This year
7 results on '"Iacobelli, Simona"'

1. Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC)

Author

Niederwieser, Christian, Iacobelli, Simona, Franke, Georg-Nikolaus, Koster, Linda, van Os, Marleen, Platzbecker, Uwe, Hübel, Kai, Scheid, Christof, Müller, Lutz Peter, Stelljes, Matthias, Morozova, Elena, Passweg, Jakob, Onida, Francesco, Dreger, Peter, Saccardi, Riccardo, Ladetto, Marco, Salmenniemi, Urpu, Bethge, Wolfgang, Poiré, Xavier, Kobbe, Guido, McLornan, Donal P., Robin, Marie, and Kröger, Nicolaus

Published
2024
Full Text
View/download PDF

2. Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT

Author

Robin, Marie, Iacobelli, Simona, Koster, Linda, Passweg, Jakob, Avenoso, Daniele, Wilson, Keith M. O., Salmenniemi, Urpu, Dreger, Peter, von dem Borne, Peter, Snowden, John A., Robinson, Stephen, Finazzi, Maria Chiara, Schroeder, Thomas, Collin, Matthew, Eder, Matthias, Forcade, Edouard, Loschi, Michael, Bramanti, Stefania, Pérez-Simón, Jose Antonio, Czerw, Tomasz, Polverelli, Nicola, Drozd-Sokolowska, Joanna, Raj, Kavita, Hernández-Boluda, Juan Carlos, and McLornan, Donal P.

Published
2024
Full Text
View/download PDF

3. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison

Author

Beelen, Dietrich Wilhelm, Iacobelli, Simona, Koster, Linda, Eikema, Dirk-Jan, van Biezen, Anja, Stölzel, Friedrich, Ciceri, Fabio, Bethge, Wolfgang, Dreger, Peter, Wagner-Drouet, Eva-Maria, Reményi, Péter, Stelljes, Matthias, Markiewicz, Miroslaw, McLornan, Donal P., Yakoub-Agha, Ibrahim, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

5. Correction: Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT

Author

Robin, Marie, Iacobelli, Simona, Koster, Linda, Passweg, Jakob, Avenoso, Daniele, Wilson, Keith M. O., Salmenniemi, Urpu, Dreger, Peter, von dem Borne, Peter, Snowden, John A., Robinson, Stephen, Finazzi, Maria Chiara, Schroeder, Thomas, Collin, Matthew, Eder, Matthias, Forcade, Edouard, Loschi, Michael, Bramanti, Stefania, Pérez-Simón, Jose Antonio, Czerw, Tomasz, Polverelli, Nicola, Drozd-Sokolowska, Joanna, Raj, Kavita, Hernández-Boluda, Juan Carlos, and McLornan, Donal P.

Published
2024
Full Text
View/download PDF

7. Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study.

Author

Niederwieser D, Hasenclever D, Berdel WE, Biemond BJ, Al-Ali H, Chalandon Y, Van Gelder M, Junghanß C, Gahrton G, Hänel M, Hehlmann R, Heinicke T, Hochhaus A, Iacobelli S, Kooy RVM, Kröger N, Janssen J, Jentzsch M, Breywisch F, Mohty M, Masouridi-Levrat S, Ossenkoppele G, Passweg J, Pönisch W, Schetelig J, Schliemann C, Schwind S, Stelljes M, Verdonck LF, Vucinic V, Löwenberg B, and Cornelissen J

Abstract

Given the selection of elderly patients with AML in first complete remission (CR1) the advantage of consolidation with allogeneic hematopoietic cell transplantation (HCT) over chemotherapy is still unclear. Newly diagnosed AML patients in CR1 aged 60-75 years were registered and a donor search initiated. After one consolidation cycle, patients with a matched donor were randomized to HCT with fludarabine/lowdose total body irradiation and cyclosporine/mycophenolate mofetil immunosuppression or conventional non-HCT. Primary outcome was restricted mean leukemia-free survival (RM-LFS) up to five years. Between 2010 and 2017, 245 patients (median age 67 years) were registered at CR1. After one consolidation, 26.9% of patients failed inclusion criteria. Of the 179 (73%) patients still on study, 75.4% had an HLA identical donor. Ten ineligible patients were excluded, and 125 randomized to HCT (n=83) or non-HCT (n=42). The primary outcome RM-LFS up to 5 years was 24.5 months (95%CI:18.9-30.1) in the HCT and 15.6 months (95%CI:10.4-20.8) in the non-HCT arm (p=0.022) due to a decrease in cumulative relapse incidence from 91.1 (95%CI:80.7-100.0) after non-HCT to 37.8 (95%CI:27.2-48.4)% after HCT (p.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results